Latest Breaking News On - சமூகம் க்கு நோயெதிர்ப்பு சிகிச்சை ஆஃப் புற்றுநோய் ஆண்டு சந்தித்தல் - Page 1 : comparemela.com

Published: Jan 11, 2021 CAMBRIDGE, Mass. (BUSINESS WIRE) Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it is expanding its pipeline of innovative vaccines with three new development programs based on the clinical success of its infectious disease vaccine portfolio to date. This announcement reflects the Company’s commitment to accelerating its infectious disease portfolio based on Moderna’s experience with its COVID-19 vaccine. The development programs announced today are mRNA vaccine candidates against seasonal flu, HIV and the Nipah virus. Moderna also announced an expansion of its respiratory syncytial virus (RSV) vaccine program into older adults.

United statesUnited kingdomIntratumoral immunoCorinne le goffLe goffRuchira glaserHead of clinical sciences for theMelinda gates foundationModerna new infectious disease vaccine development programsEuropean unionVaccine research centerUs department of healthNational institutes of healthHuman servicesDrug administrationDevelopment authority